UC San Francisco interventional cardiologists and interventional echocardiographers recently performed the health system’s first commercial transcatheter tricuspid valve replacement procedure using the Edwards EVOQUE system. The novel and minimally invasive cardiac procedure was recently approved for use within the U.S. by the Food and Drug Administration. The UCSF team is the first to perform the commercial procedure across the UC system and in San Francisco, and is one of only a handful of centers currently performing the procedure nationally.